Monocyte and Haematopoietic Progenitor Reprogramming As Common Mechanism Underlying Chronic Inflammatory and Cardiovascular Diseases

Overview

Journal Eur Heart J

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2017 Oct 26

PMID 29069365

Citations 34

Authors

Renate M Hoogeveen

Matthias Nahrendorf

Niels P Riksen

Mihai G Netea

Menno P J de Winther

Esther Lutgens

Borge G Nordestgaard

Michel Neidhart

Erik S G Stroes

Alberico L Catapano

Siroon Bekkering

Affiliations

Soon will be listed here.

Abstract

A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

Citing Articles

Optimal medical therapy, clinical outcome and its predictors in patients with acute coronary syndrome after discharge with secondary prevention medications at University of Gondar Comprehensive Specialized Hospital, North West Ethiopia, 2023: A....

Geremew G, Alemayehu T, Bekalu A, Mengistu M, Anberbr S, Getahun A BMC Cardiovasc Disord. 2024; 24(1):533.

PMID: 39363265 PMC: 11448055. DOI: 10.1186/s12872-024-04199-x.

The causal relationship between triglycerides and myocardial infarction: A two-sample Mendelian randomization.

Kong L, Yang Z, Chen X, Quan X, Liu H, Qiu A Medicine (Baltimore). 2024; 103(37):e39595.

PMID: 39287313 PMC: 11404938. DOI: 10.1097/MD.0000000000039595.

Atypical monocyte dynamics in healthy humans in response to fasting and refeeding are distinguished by fasting HDL and postprandial cortisol.

Snodgrass R, Stephensen C, Laugero K Am J Physiol Endocrinol Metab. 2024; 327(2):E229-E240.

PMID: 38958546 PMC: 11427091. DOI: 10.1152/ajpendo.00158.2024.

The Fibrinogen-to-Albumin Ratio Is Associated with Poor Prognosis in Patients with Coronary Artery Disease: Findings from a Large Cohort.

Hou X, Wu T, Zheng Y, Yang H, Yang Y, Ma Y J Cardiovasc Transl Res. 2023; 16(5):1177-1183.

PMID: 37349658 DOI: 10.1007/s12265-023-10402-9.

Shifts in the immunoepigenomic landscape of monocytes in response to a diabetes-specific social support intervention: a pilot study among Native Hawaiian adults with diabetes.

Dye C, Corley M, Ing C, Lum-Jones A, Li D, Mau M Clin Epigenetics. 2022; 14(1):91.

PMID: 35851422 PMC: 9295496. DOI: 10.1186/s13148-022-01307-6.

References

Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd J . Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015; 8(2):121-30. PMC: 6855915. DOI: 10.1016/j.jcmg.2014.10.009. View

Mann B, Johnson J, He K, Sridhara R, Abraham S, Booth B . Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007; 13(8):2318-22. DOI: 10.1158/1078-0432.CCR-06-2672. View

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

van der Valk F, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul J . Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016; 134(8):611-24. PMC: 4995139. DOI: 10.1161/CIRCULATIONAHA.116.020838. View

Libby P, Hansson G . Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015; 116(2):307-11. PMC: 4299915. DOI: 10.1161/CIRCRESAHA.116.301313. View

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

Wollenweber T, Roentgen P, Schafer A, Schatka I, Zwadlo C, Brunkhorst T . Characterizing the inflammatory tissue response to acute myocardial infarction by clinical multimodality noninvasive imaging. Circ Cardiovasc Imaging. 2014; 7(5):811-8. DOI: 10.1161/CIRCIMAGING.114.001689. View

Marnane M, Merwick A, Sheehan O, Hannon N, Foran P, Grant T . Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012; 71(5):709-18. DOI: 10.1002/ana.23553. View

10.

Assmus B, Iwasaki M, Schachinger V, Roexe T, Koyanagi M, Iekushi K . Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. Eur Heart J. 2011; 33(15):1911-9. DOI: 10.1093/eurheartj/ehr388. View

11.

Ridker P, Luscher T . Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014; 35(27):1782-91. PMC: 4155455. DOI: 10.1093/eurheartj/ehu203. View

12.

Kokkola R, Sundberg E, Ulfgren A, Palmblad K, Li J, Wang H . High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002; 46(10):2598-603. DOI: 10.1002/art.10540. View

13.

Arts R, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R . Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016; 17(10):2562-2571. PMC: 5177620. DOI: 10.1016/j.celrep.2016.11.011. View

14.

Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, De La Cruz-Hernandez E, Herrera L . Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008; 34(3):206-22. DOI: 10.1016/j.ctrv.2007.11.003. View

15.

Wyss C, Neidhart M, Altwegg L, Spanaus K, Yonekawa K, Wischnewsky M . Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J. 2010; 31(12):1457-69. DOI: 10.1093/eurheartj/ehq084. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Fredman G, Tabas I . Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol. 2017; 187(6):1211-1221. PMC: 5455064. DOI: 10.1016/j.ajpath.2017.01.018. View

18.

Libby P, Tabas I, Fredman G, Fisher E . Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114(12):1867-79. PMC: 4078767. DOI: 10.1161/CIRCRESAHA.114.302699. View

19.

Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R . A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014; 236(1):91-100. DOI: 10.1016/j.atherosclerosis.2014.06.008. View

20.

Boring L, Gosling J, Cleary M, Charo I . Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394(6696):894-7. DOI: 10.1038/29788. View